Radiotherapy in metastatic bladder cancer

Abstract

Abstract Purpose To review available and emerging evidence of radiotherapy for symptom management and disease control in metastatic bladder cancer. Methods A literature search and subsequent cross-referencing were carried out for articles in the PubMed and Scopus databases using terms ‘radiotherapy’ OR ‘palliative radiation therapy’ with ‘metastatic bladder cancer’ OR ‘advanced bladder cancer’ between 1990 and 2023, excluding articles with no English translation. Results Palliative radiotherapy is an effective and accessible treatment for the alleviation of haematuria and pain due to the primary and metastatic disease. With growing recognition of oligometastatic disease state at diagnosis, response, or progression, radiotherapy can consolidate response by ablating residual or resistant lesions. Experience with other primary cancers supports positive impact of radiotherapy on disease control, quality of life, and survival in oligometastatic stage, without significant adverse effects. Alongside immune checkpoint inhibitors, fibroblast growth receptor inhibitors, and antibody–drug conjugates, the immunomodulatory potential of radiotherapy is being explored in combination with these systemic therapies for metastatic bladder cancer. Conclusion Radiotherapy is an effective, safe, and accessible treatment modality for palliation as well as disease control in various clinical settings of metastatic bladder cancer. Its role in oligometastatic stage in combination with systemic therapy is expected to expand with emerging evidence.